Echo IQ entered into a partnership with Hydrix Limited

Echo IQ (ASX: EIQ) entered into a commercial deal with Hydrix Limited, to offer its EchoSolv platform in Australia, New Zealand, and Singapore. Aortic stenosis is one structural cardiac ailment that is associated with a significant risk of patients, according to the cloud-based technology EchoSolv.

A quicker time to treatment is made possible by EchoSolv's automated analysis and risk assessment of ECG data in less than 3 seconds, which aids enhanced diagnosis. Building on the Hydrix Brand, this business partnership with Echo IQ will take advantage of the knowledge in cardiac health innovation and distribution. In Australia, New Zealand, and Singapore, ten thousand aortic valve replacements and one million echocardiograms are performed annually.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com